This information is intended for U.S. healthcare professionals and/or
healthcare professionals involved in healthcare reimbursement.
This site is intended for U.S. residents 18 years of age or older.
Live Support
1-800-861-0048
8 AM to 8 PM ET, Mon–Fri
We’d love your feedback on your experience today.
Please take this quick survey to help us continue to provide you with information
Supporting patient access
BMS Access Support® may help support patient access by conducting benefits reviews and offering prior authorization and appeals process assistance for enrolled patients. Additionally, the information below provides product-specific billing and diagnosis codes, reimbursement and coding guides, distribution information, and additional coverage support offerings. To view available coding and coverage information, please select your patient’s prescribed medication.
Additional eligibility criteria and terms may apply. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
Read more about our coverage support offerings
Benefits Reviews
- Once a patient is enrolled in BMS Access Support, we can review their insurance coverage and provide a summary of benefits within approximately 24 hours*
- A benefits review may help determine whether or not a medication is covered, if a PA is required, and estimated patient out-of-pocket costs
*BMS Access Support Data - Benefits review. Accessed August 2022.
Prior Authorization (PA) and Appeals Assistance
- Use the BMS Access Map to identify plan-specific PA requirements
- View our forms and resources page for helpful support tools, including appeals letter templates and medical necessity letters
Annual Reverification
- Reverification of benefits is available upon request to confirm a patient’s benefits for the new year
- Connect with your local Access and Reimbursement Manager for more information
Medication Menu
EMPLICITI®
(elotuzumab)
Indication(s) Important Safety Information U.S. Full Prescribing Information
The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
Reimbursement and Coding Guide
for EMPLICITI
Filter results by:
Healthcare Common Procedure Coding System (HCPCS) Codes1
Issued by CMS
| J9176 Copy | Injection, elotuzumab, 1 mg |
Providers and suppliers are required to report the JW modifier on Part B drug claims for discarded drugs and biologicals. Also, providers and suppliers must document the amount of discarded drugs or biologicals in Medicare beneficiaries’ medical records.2
Revenue Codes (for Use in the Hospital Outpatient Setting)3
| 0636 Copy | Drugs requiring detailed coding |
| 0335 Copy | Chemotherapy administration, IV |
| 0260 Copy | IV Therapy-General |
Current Procedural Terminology (CPT)4,†
| 96413 Copy | Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug |
| 96415 Copy | Each additional hour
|
National Drug Codes (NDC)5
Issued by the FDA
Note: Payers require the submission of the 11-digit NDC on healthcare claim forms. Please use the 11-digit codes shown here.
| 00003-2291-11 Copy | 300 mg single-dose vial |
| 00003-4522-11 Copy | 400 mg single-dose vial |
International Classification of Diseases, Tenth Revision, Clinical Modification Diagnosis Codes (ICD-10-CM)6
| C90 Copy | Multiple myeloma and malignant plasma cell neoplasms |
| C90.0 Copy | Multiple myeloma |
| C90.00 Copy | Multiple myeloma not having achieved remission |
| C90.02 Copy | Multiple myeloma in relapse |
| Z51.12 Copy | Encounter for antineoplastic immunotherapy If infusion for antineoplastic immunotherapy is the only reason for the patient encounter, physicians and hospitals may report ICD-10-CM code “Z51.12 Encounter for antineoplastic immunotherapy” as the primary diagnosis. |
Coding for EMPLICITI is dependent on the insurer and the care setting in which the drug will be administered. Healthcare providers need to make coding decisions based on the diagnosis and treatment of each patient and the specific insurer requirements.
Please see U.S. Full Prescribing Information for EMPLICITI.
*Healthcare providers should code healthcare claims based upon the service that is rendered, the patient’s medical record, the coding requirements of each health insurer, and best coding practices. Coding guidance provided under this heading does not provide a guarantee of reimbursement and should be considered together with all applicable coding guidance and standards. All of the coding information presented by this website is applicable to outpatient procedures only.
†CPT codes and descriptions only are ©2023 by American Medical Association (AMA). All rights reserved. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association.
References:
- American Medical Association. 2020 HCPCS Level II. Professional ed. Chicago, IL: American Medical Association; 2020.
- Centers for Medicare & Medicaid Services. MLN Matters, Number MM9603 Revised. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM9603.pdf. Revised June 10, 2016. Accessed August 2, 2023.
- Palmetto GBA. Medicare Part A Billing Guide. March 2017. http://www.palmettogba.com/Palmetto/Providers.Nsf/files/Part_A_Billing_Guide.pdf/$File/Part_A_Billing_Guide.pdf. Accessed August 2, 2023.
- American Medical Association. Current Procedural Terminology 2020. Professional ed. Chicago, IL: American Medical Association; 2019.
- EMPLICITI [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
- Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. https://www.cms.gov/medicare/coding-billing/icd-10-codes/2023-icd-10-cm. Accessed August 2, 2023.
EMPLICITI may be purchased through the distributors listed below.
Physician Offices
| Authorized Distributor | Phone Orders | Fax Orders and Website |
|---|---|---|
| Cardinal Health Specialty Pharmaceutical Distribution | 1-877-453-3972 | https://specialtyonline.cardinalhealth.com |
| CuraScript Specialty Distribution | 1-877-599-7748 | https://www.curascriptsd.com |
| McKesson Specialty Health | 1-800-482-6700 | https://mscs.mckesson.com |
| Morris & Dickson Specialty | 1-800-710-6100 | Fax: 1-318-524-3096 https://www.mdspecialtydist.com |
| Oncology Supply | 1-800-633-7555 | https://www.oncologysupply.com |
For offices that prefer to use the services of a specialty pharmacy, specialty pharmacies can obtain EMPLICITI from the below-listed distributors.
Hospitals and Infusion Centers
| Specialty Distributor | Phone Orders | Fax Orders and Website |
|---|---|---|
| ASD Healthcare | 1-800-746-6273 | Fax: 1-800-547-9413 https://www.asdhealthcare.com |
| Cardinal Health Specialty Pharmaceutical Distribution | 1-866-677-4844 | Fax: 1-614-553-6301 https://orderexpress.cardinalhealth.com |
| DMS Pharmaceutical Group, Inc. | 1-877-788-1100 | Fax: 1-847-518-1105 www.dmspharma.com |
| McKesson Plasma and Biologics | 1-877-625-2566 | Fax: 1-888-752-7626 https://connect.mckesson.com |
| Morris & Dickson Specialty | 1-800-710-6100 | Fax: 1-318-524-3096 https://www.mdspecialtydist.com |
Puerto Rico Hospitals and Clinics
| Authorized Distributor | Phone Orders | Fax Orders and Website |
|---|---|---|
| Amerisource Bergen Puerto Rico |
1-844-222-2273 | https://abcorder.amerisourcebergen.com |
| Cardinal Puerto Rico (Borschow) | 1-787-625-4200 | https://www.cardinalhealth.pr |
| Cesar Castillo, Inc. | 1-787-641-5242 (Hospitals) 1-787-641-5082 (Specialty Pharmacies) |
Fax: 1-787-999-1614 https://www.facilfarmaciacci.com |
Above information is accurate as of 12/23.
The EMPLICITI distribution program includes extended payment terms to Bristol Myers Squibb authorized EMPLICITI distributors. Healthcare providers and institutions should contact their EMPLICITI distributor to understand specific payment terms that may be available to them from their distributor.
Please see U.S. Full Prescribing Information for EMPLICITI.
FDA Approval Letters as Posted by the FDA:
FDA Letter — in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor
View Letter
FDA Letter — in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma after one to three prior therapies
View LetterPlease see U.S. Full Prescribing Information for EMPLICITI.
Claim Forms for Outpatient Administration – Tutorial
Physician Office
CMS-1500
Hospital Outpatient
UB-04/CMS-1450See Payer Policy Details
See Payer Policy Details
Learn about payer information by state for applicable treatments.
